Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Cipla
Chinese Patent Office
Fuji
Baxter
Healthtrust
Citi
Moodys
Express Scripts

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202020

« Back to Dashboard

NDA 202020 describes RAYOS, which is a drug marketed by Horizon Pharma and is included in one NDA. It is available from one supplier. There are eight patents protecting this drug and one Paragraph IV challenge. Additional details are available on the RAYOS profile page.

The generic ingredient in RAYOS is prednisone. There are sixteen drug master file entries for this compound. Fifty-eight suppliers are listed for this compound. Additional details are available on the prednisone profile page.
Summary for 202020
Tradename:RAYOS
Applicant:Horizon Pharma
Ingredient:prednisone
Patents:8
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
Inflammatory Bowel Disease Agents
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 202020
Suppliers and Packaging for NDA: 202020
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020 NDA Horizon Pharma Inc. 75987-020 N 75987-020-01
RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020 NDA Horizon Pharma Inc. 75987-020 N 75987-020-02

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, DELAYED RELEASE;ORALStrength1MG
Approval Date:Jul 26, 2012TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Mar 14, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE
Patent:➤ Try a Free TrialPatent Expiration:Mar 14, 2020Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE
Patent:➤ Try a Free TrialPatent Expiration:Apr 23, 2024Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Chinese Patent Office
Daiichi Sankyo
Cipla
Moodys
Teva
QuintilesIMS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.